GeNOsys sponsors Phase I safety trial in collaboration with Nitric Solutions

GeNOsys, Inc. (OTCBB: GNYS) today announced they are sponsoring a Phase I safety trial in collaboration with Nitric Solutions Inc. GeNOsys will be testing their patented nitric oxide generator and nitric oxide producing formula for safety and effectiveness in treating disease. In a parallel study Nitric Solutions will be testing the efficacy of their prophilactic nitric oxide producing formula Nitrisol^TM. The studies will be conducted in a Canadian government research facility by Dr. Kevin Kane; results are expected to be available within 30 days. GeNOsys will demonstrate that nitric oxide can be safely administered with the generator in compliance with FDA guidelines. Nitric Solutions Inc. will show the antimicrobial effectiveness of Nitrisol^TM in the treatment of H1N1.

“We are pleased to join Nitric Solutions in this study because it accelerates our timeline”

"We are pleased to join Nitric Solutions in this study because it accelerates our timeline," stated Mr. John W.R. Miller, Chairman of the Board. "This study accomplishes a key milestone in our product development plan. The information obtained will demonstrate the safety of our generator and establish the legitimacy of its bedside use. This study will allow GeNOsys to participate in the Phase II human clinical trial evaluating the therapeutic use of gaseous nitric oxide which is scheduled by Dr. Kevin Kane to begin this fall."